| Name | Title | Contact Details |
|---|
LiquidM is the only white-labeled Mobile Advertising Management Platform (MAMP), which allows media buyers to optimize their processes across the full range of premium to performance advertising. Build from the ground up for mobile, LiquidM’s white-labeled Mobile Advertising Management Platform (MAMP) allows mobile media buyers to optimize their management processes across the full range of premium to performance advertising. LiquidM provides a business model-agnostic full stack to manage and optimize mobile advertising campaigns. LiquidM’s modular, cloud-based SaaS replaces Build-Your-Own (BYO) or inadequate point solutions of ad tech infrastructure with a standardized, open platform that is customizable to individual needs. LiquidM’s unique combination of delivering quality and performance in one platform allows for reach extension through real-time bidding, targeting, rich media formats and the ability to work closely with mobile operators.
SpireMedia is a Denver, CO-based company in the Software and Internet sector.
Addepar is a leading provider of technology for the wealth management industry. The company`s performance reporting and analytics platform aggregates portfolio, market, and client data all in one place. It provides asset owners and advisors a clearer financial picture at every level, allowing them to make more informed and timely investment decisions. Addepar works with leading financial advisors, family offices, and large financial institutions that manage over $1.3 trillion of assets on the company`s platform. In 2018, Addepar was named as a Forbes Fintech 50 and received Morgan Stanley`s Fintech Award for making significant impact to the firm`s mission of continuous innovation. Addepar is headquartered in Silicon Valley and has offices in New York City, Chicago, and Salt Lake City.
A leader in communication innovation since 2004, we create opportunity for service providers by simplifying complex challenges.
Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.